Nanobiotix is a clinical-stage biotechnology company, not directly involved in space exploration or manufacturing, but focused on nanomedicine to transform cancer treatment. Their lead product, NBTXR3, uses nanotechnology to enhance the effectiveness of radiotherapy. While not a space industry player, Nanobiotix is mentioned in the context of Karista VC, a venture capital firm that invests in space-related ventures.
All verified mentions of this organization in source documents.
Since its creation in 2001, Karista has supported more than 90 companies in Europe and has financed companies including Sequans Communications, Nanobiotix, and Comitéo.